AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JAN 25 - (NewsRx.com) -- The new drug toremifene, a drug with anti-estrogen activity similar to tamoxifen, does not cause as many liver-related disorders in breast cancer patients, according to new research.
Fatty liver was observed in as many as 30% of women with breast cancers who were taking tamoxifen, N. Hamada et al. stated recently in the International Journal of Oncology. Hamada's research team works at Kochi Medical School in Japan.
"It is urgent to elucidate the frequency and the degree of fatty liver induced by toremifene, an analogue of tamoxifen, which is also used in breast cancer," the group commented.
Hamada's study enlisted 52 women with breast cancer to take three to five years of adjuvant therapy with toremifene. All of the women were on breast conservation treatment regimens.
At yearly intervals, the women underwent computed tomography (CT) to assess liver status. Only four of the women evidenced varying degrees of fatty liver based on CT imaging; upon analysis of actual liver tissues, one of these women was diagnosed with non-alcoholic steatohepatitis (NASH).
"The incidence of toremifene-induced fatty liver was significantly lower than that induced by tamoxifen. Accordingly, in terms of fatty liver and NASH, toremifene ...